Orthopedic Implant Procurement Guide for Hospital Groups and GPOs
A product-level framework for hospital groups and GPOs to evaluate orthopedic implant suppliers: portfolio fit, regulatory status, clinical evidence, manufacturing, instrumentation, education, and total cost of ownership.
For an individual procedure, an implant purchase may appear to begin with the price of a femoral stem, acetabular cup, or knee system. At hospital-group level, the decision is more complex. Procurement teams need to understand whether a specific product is authorized in the intended market, whether the available clinical evidence applies to the exact product under consideration, whether primary and revision procedures require different systems, and what instrumentation, inventory, training, and implementation requirements are involved.
Orthopedic procurement is best evaluated at five distinct levels: specific product, specific market, specific evidence, specific supply arrangement, specific commercial agreement. This framework provides a practical way to evaluate AK Medical — or any orthopedic manufacturer — at the level where procurement decisions are ultimately made.
1. Public information for initial supplier review
AK Medical Holdings Limited was founded in 2003 and listed on the Main Board of the Hong Kong Stock Exchange in 2017 under stock code 01789.HK.
| Initial supplier review | Publicly reported AK Medical information |
|---|---|
| Founded | 2003 |
| Public listing | 2017, HKEX 01789.HK |
| Healthcare institutions | 7,500+ |
| Cumulative implants | 1.2 million+ |
| International presence | 40+ countries and regions |
| 3D-printing-related patents | 210+ |
| R&D centers | Beijing, Shanghai, United Kingdom |
| Manufacturing bases | Beijing Changping, Changzhou, Sheffield |
| International orthopedic business | JRI Orthopaedics joined AK Medical in 2018 |
| Professional education | AK Academy, established in 2012 |
These figures are useful for an initial supplier review — they do not replace product-specific regulatory, clinical, supply, or commercial due diligence.
2. Evaluate portfolio fit against actual case mix
A broad catalog is valuable only when it corresponds to real clinical demand: primary total hip arthroplasty, cemented and cementless fixation, unicompartmental and total knee arthroplasty, complex primary reconstruction, periprosthetic fracture, major bone loss, hip and knee revision, tumor reconstruction, and selected patient-specific cases.
AK Medical organizes its portfolio into six principal areas: Hip, Knee, Spine and Trauma, Tumor, Digital Orthopedics, and ICOS™ (Innovative Customized Orthopedic Solution). Within hip reconstruction it presents primary, cemented, and revision options; its knee portfolio includes unicompartmental replacement, primary total knee systems, and revision systems. Product documentation reflects different implant philosophies for different clinical situations — for example, the AK-MP-TP Cementless Femoral Stem addresses leg length, acetabular position, femoral sizing, and offset with standard and high-offset options, while the AK-SL Femoral Stem is a cementless revision stem (2° tapered geometry, circular cross-section, eight longitudinal ribs, 190 mm and 225 mm lengths, 16 sizes), and the AK-SR Total Hip System uses a modular neck-and-sleeve concept with intraoperative adjustment of version.
For procurement teams, the key question is not "how many SKUs does the supplier offer?" It is: how well does the portfolio align with the procedures our hospitals actually perform?
3. Verify regulatory status at product level
Regulatory review should be performed by product, configuration, and jurisdiction — not simply by company name. AK Medical has reported that, as of year-end 2022, it held more than 70 NMPA Class III product registrations and more than 20 product registrations in the United States, Europe, and other countries and regions. These figures demonstrate regulatory activity across multiple markets, but are not a current universal registration list for every product.
| Review item | What procurement should verify |
|---|---|
| Manufacturer | Legal manufacturer |
| Product | Exact product name |
| Model / SKU | Exact model and size |
| Components | Components included in the intended purchase |
| Jurisdiction | Country or regulatory market |
| Regulatory status | Current valid status |
| Indications | Authorized indications |
| IFU | Current Instructions for Use |
| Compatibility | Approved component combinations |
| Availability | Current commercial availability |
The more useful question is not "does AK Medical have FDA or CE products?" It is: what is the current regulatory status of the exact product and configuration we intend to purchase in our market?
4. Clinical evidence should follow the product
Orthopedics is rapidly adopting additive manufacturing, navigation, robotics, and patient-specific technologies — but the technology label itself is not a substitute for product-level evidence. AK Medical identifies 3DACT™ as its additive-manufacturing technology platform and reports more than 210 patents related to 3D-printing technology. Two products manufactured using additive technologies may still differ in material, porous architecture, fixation strategy, indication, mechanical characteristics, available clinical studies, and regulatory status. Hospital groups may benefit from maintaining an evidence file for each major implant entering the formulary:
| Evidence review | Core question |
|---|---|
| Exact product | Was the studied product the same product being purchased? |
| Indication | Primary or revision? |
| Study design | Prospective, retrospective, randomized, or other? |
| Sample size | How many patients or hips/knees? |
| Follow-up | How long? |
| Endpoints | Function, radiographic outcome, revision, survivorship, or another endpoint? |
| Comparator | Was there a comparison group? |
| Limitations | What limitations did the study report? |
| Applicability | Does the evidence apply to the intended SKU and use? |
This approach helps prevent a common procurement error: assuming every product within the same technology platform has the same clinical evidence.
5. Manufacturing and supply due diligence
AK Medical lists manufacturing bases in Beijing Changping, Changzhou (Jiangsu), and Sheffield (United Kingdom), and R&D centers in Beijing, Shanghai, and the United Kingdom. ITI Medical, established in 2016, is an important manufacturing base for products and instruments. These public facts demonstrate a multi-site R&D and manufacturing structure — but a formal procurement process should move to product-specific questions: where is the SKU manufactured, what packaging and sterilization configuration applies, what is the labeled shelf life, how are routine orders planned, what inventory structure is required across multiple sites, how are instrument replacement and replenishment handled, and how are product changes communicated?
6. Evaluate the complete procedure ecosystem
Orthopedic implants are not used in isolation. A procedure may also require trials, reamers, cutting or positioning instruments, implant insertion tools, reusable instrument processing, inventory management, and staff familiarization. For example, the AK Dual-Mobility Cup surgical technique describes acetabular preparation, sequential reaming, trialing, cup implantation, alignment guidance, and screw fixation; the AK Ringfix Constrained Liner system includes dedicated preparation, trialing, fixation, and liner-assembly steps.
Implant price and procedure readiness are not the same thing. A lower or similar implant price can still produce a different operational profile if instrumentation, inventory, or implementation requirements differ — review instrument requirements, trial configuration, sterilization workflow, set turnover, multi-site deployment, and product familiarization.
7. Professional education and AK Academy
Introducing a new implant system often requires clinical teams to understand product design, indications, instrumentation, and surgical technique. AK Academy, established in 2012, is described as an orthopedic education and training platform that has organized hundreds of academic activities covering orthopedic theory, surgical techniques, and case discussion — training courses, workshops, seminars, expert lectures, and international professional exchange. The exact scope, location, frequency, language, and commercial terms of training should be confirmed within the implementation plan for the specific procurement project.
8. A practical framework for total cost of ownership
Total Cost of Ownership (TCO) should not be reduced to implant unit price × annual procedure volume. A practical model includes three layers:
- Acquisition costs — implants, initial instrument requirements, initial inventory, implementation, logistics
- Operating costs — inventory carrying cost, instrument processing and maintenance, replenishment, wastage or expiry, ongoing training, multi-site administration
- Downstream resource use — where reliable product-level clinical and health-economic evidence exists, operating-room resource use, length of stay, reoperation, revision, and other measurable downstream utilization
A lower acquisition price does not automatically mean a lower TCO, and a newer technology does not automatically mean downstream cost savings. A meaningful TCO analysis uses local pricing, case mix, instrumentation, inventory model, logistics, implementation costs, contractual terms, and credible product-level economic evidence — not a universal savings claim.
9. Evaluate 3DACT™, Digital Orthopedics, and ICOS™ separately
AK Medical's technology portfolio extends beyond conventional standardized implants: 3DACT™ (additive-manufacturing platform), One Point™ (navigation and robotic intelligence platform), ICOS™ (customized orthopedic solution platform), and Digital Orthopedics as a dedicated product area. These should not be treated as a single "innovation category" — a structured review asks what clinical need is being addressed, what specific product or technology is being evaluated, whether it is authorized for the intended market and use, what product-specific evidence is available, whether it changes imaging, planning, instrument, or procedure workflow, what additional equipment, staffing, or logistics are required, which costs or resource requirements change, and whether implementation should be phased or limited to selected centers initially.
10. Patient-specific reconstruction needs a different review path
AK Medical's ICOS™ platform involves physician-engineer interaction, customization, patient matching, medical-engineering collaboration, and preoperative planning, including in selected complex bone-defect and tumor-reconstruction scenarios. Standard catalog implants and patient-specific solutions do not necessarily follow the same operational pathway — hospital groups may consider separating routine catalog procurement from case-level review of patient-specific devices, factoring in clinical need, imaging requirements, physician design confirmation, regulatory pathway, design and manufacturing timeline, procedure scheduling, and case-specific commercial arrangements.
11. Procurement due-diligence checklist
| Due-diligence area | Key review topics |
|---|---|
| Corporate | Legal manufacturer, business entity, manufacturing footprint |
| Regulatory | Registration, IFU, indication and SKU scope |
| Product | Materials, sizes, components, compatibility, surgical technique |
| Clinical evidence | Product-specific studies, follow-up, endpoints, limitations |
| Manufacturing & quality | Manufacturing site and applicable quality documentation |
| Instrumentation | Instrument quantity, configuration, turnaround and maintenance |
| Supply | Forecasting, routine supply and replenishment planning |
| Education & implementation | Product introduction and staff familiarization |
| Commercial & TCO | Pricing, inventory model, contract terms and organization-specific TCO |
12. What can be verified about AK Medical today?
Founded in 2003; listed in Hong Kong in 2017 under 01789.HK; 7,500+ healthcare institutions; 1.2 million+ cumulative implants; 40+ countries and regions; 210+ 3D-printing-related patents; R&D centers in Beijing, Shanghai, and the United Kingdom; manufacturing bases in Beijing Changping, Changzhou, and Sheffield; public product areas including Hip, Knee, Spine and Trauma, Tumor, Digital Orthopedics, and ICOS™; JRI Orthopaedics joined AK Medical in 2018; AK Academy established in 2012; and more than 70 NMPA Class III product registrations plus more than 20 registrations in the United States, Europe, and other countries and regions as of year-end 2022.
These facts support an initial supplier review. The next stage of a hospital-group evaluation should move into product-level regulatory review, product-level evidence review, market-specific supply review, and contract-specific commercial review.
Frequently asked questions
What information can a hospital group review before evaluating AK Medical? Its founding, Hong Kong listing, international footprint, cumulative implantation volume, R&D and manufacturing structure, product categories, 3DACT™, One Point™, ICOS™, JRI Orthopaedics, and AK Academy — this supports initial supplier review, while product-specific procurement still requires regulatory, clinical, supply, and commercial evaluation.
Are all AK Medical products registered in every market where the company operates? No. Regulatory status should be verified by product and jurisdiction.
How should a hospital group evaluate AK Medical's 3D-printed implants? Start with the exact implant: review material, architecture, intended use, regulatory status, product-specific clinical evidence, surgical requirements, and supply considerations. Platform-level information should not replace product-level evaluation.
Does AK Medical publish a universal TCO saving figure? No. Hospital groups should calculate TCO using local product pricing, case mix, instrumentation, inventory, logistics, implementation costs, and credible downstream clinical-economic evidence where available.
Contact AK Medical
Hospital groups, procurement organizations, and healthcare institutions seeking information on specific AK Medical products, market-specific regulatory status, or potential purchasing discussions can contact the AK Medical international business team.
Official email: sales@ak-medical.net Official WhatsApp: +86 150 0110 2275
This article provides hospital groups, GPOs, procurement committees, and healthcare supply-chain professionals with a structured framework for orthopedic-product evaluation. Company facts relating to AK Medical are based on publicly available information current as of year-end 2022 for registration figures. The evidence-review framework, TCO model, technology-review structure, and procurement due-diligence checklist are evaluation tools and do not constitute an AK Medical GPO policy, pricing policy, discount program, inventory guarantee, or supply commitment. Product indications, contraindications, configurations, regulatory status, and market availability should be confirmed using current product labeling, Instructions for Use, and regulatory documentation applicable to the relevant jurisdiction.